Maravai LifeSciences Holdings, Inc. (MRVI)
| Market Cap | 6.34B |
| Revenue (ttm) | 920.28M |
| Net Income (ttm) | 247.82M |
| Shares Out | 255.21M |
| EPS (ttm) | 1.84 |
| PE Ratio | 13.49 |
| Forward PE | 14.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,725,614 |
| Open | 25.93 |
| Previous Close | 26.03 |
| Day's Range | 24.18 - 25.93 |
| 52-Week Range | 23.05 - 63.55 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 35.70 (+43.8%) |
| Earnings Date | Aug 4, 2022 |
About MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of var... [Read more...]
Financial Performance
In 2021, MRVI's revenue was $799.24 million, an increase of 181.33% compared to the previous year's $284.10 million. Earnings were $182.04 million, an increase of 104.60%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for MRVI stock is "Buy." The 12-month stock price forecast is 35.7, which is an increase of 43.78% from the latest price.
News
3 of the Best Bear Market Buys for August
Buying all three of these stocks would give you some great diversification in toys, tech, and healthcare.
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 Earnings and Revenues Beat Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 20% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the ...
CORRECTION: Maravai Lifesciences Reports Second Quarter 2022 Financial Results
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, August 4th, by Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), please note that a variety of c...
Maravai Lifesciences Reports Second Quarter 2022 Financial Results
Record First Half Revenue, EBITDA, Adjusted EBITDA and EPS Record First Half Revenue, EBITDA, Adjusted EBITDA and EPS
Maravai LifeSciences Holdings, Inc. (MRVI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Maravai LifeSciences Holdings, Inc. (MRVI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Beaten-Down Stocks That Could Soar in the Second Half of 2022
Each of these stocks is ready for a rebound.
Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 4, 2022
SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to ...
TriLink BioTechnologies, part of Maravai LifeSciences, Expands R&D Leadership Team
Appoints Dr. Kate Broderick as Senior Vice President of Research and Development Appoints Dr. Kate Broderick as Senior Vice President of Research and Development
TriLink BioTechnologies, Part of Maravai LifeSciences, Announces Cooperative Agreement With Department of Defense
DOD to fund planned manufacturing expansion and to prepare the U.S. for a rapid response to the next pandemic as part of Industrial Base Expansion DOD to fund planned manufacturing expansion and to prep...
Maravai LifeSciences Announces May and June 2022 Investor Conference Schedule
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to part...
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 25.58% and 6.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for ...
Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 5, 2022
SAN DIEGO, April 21, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to...
BIO-TECHNE AND CYGNUS TECHNOLOGIES, PART OF MARAVAI LIFESCIENCES, INTRODUCE NEW SIMPLE PLEX HEK 293 HCP 3G IMMUNOASSAY
MINNEAPOLIS, April 12, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Cygnus Technologies, part of Maravai LifeSciences (NASDAQ: MRVI), announced today the launch of the Simple Plex™ HEK...
1 Biotech Stock Investors Should Know About
It's selling shovels amid the gold rush in mRNA medicines.
Wall Street Analysts See a 38% Upside in Maravai LifeSciences Holdings, Inc. (MRVI): Can the Stock Really Move This H...
The consensus price target hints at a 38.1% upside potential for Maravai LifeSciences Holdings, Inc. (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward t...
Maravai LifeSciences Announces March 2022 Investor Conference Schedule
SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to pa...
Sail Through the Choppy Market With These 4 Low-Beta Stocks
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.
Can Maravai LifeSciences Holdings, Inc. (MRVI) Run Higher on Rising Earnings Estimates?
Maravai LifeSciences Holdings, Inc. (MRVI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can Maravai LifeSciences Holdings, Inc. (MRVI) Climb 56% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 55.8% upside potential for Maravai LifeSciences Holdings, Inc. (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward t...
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 Earnings and Revenues Beat Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 18.42% and 10.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead ...
Maravai LifeSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Updates 2022 Financial Guidance
SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, ...
3 Biotech Stocks That Could Deliver 5X Gains by 2030
They're risky. But they could also be huge winners.
Maravai LifeSciences Acquires MyChem, a Leader in Proprietary Ultra-Pure Nucleotides
MyChem's nucleotide synthesis methods are highly complementary to Maravai's TriLink mRNA technologies
Maravai LifeSciences Announces Upcoming Investor Events
R&D Day - January 28, 2022
Maravai LifeSciences Announces Debt Repricing
Lowers Interest Rates on Current Debt to Provide Approximately $6.8 Million in Annual Interest Savings Lowers Interest Rates on Current Debt to Provide Approximately $6.8 Million in Annual Interest Savings